Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families

Author:
  • Anna Måsbäck
  • Håkan Olsson
  • Johan Westerdahl
  • Therese Törngren
  • Åke Borg
  • Nils Jonsson
  • Christian Ingvar
Publishing year: 2002
Language: English
Pages: 549-557
Publication/Series: Melanoma Research
Volume: 12
Issue: 6
Document type: Journal article
Publisher: Lippincott Williams & Wilkins

Abstract english

Primary cutaneous malignant melanomas (CMMs) from 26 individuals belonging to nine families with an identified CDKN2A mutation were clinically and histopathologically compared with 78 matched CMM controls and with a population-based series of CMMs (n=667). All tumours were histopathologically re-examined. CDKN2A-associated cases were significantly less invasive compared with the matched controls, with an adjusted odds ratio (adjOR) of 2.9 and a 95% confidence interval (CI) of 1.0-8.1 (P=0.04). According to the odds ratio (OR) values, CDKN2A-associated cases seemed to have tumours more often located on the head and neck (adjOR 2.9, 95% CI 0.6-13.7), with less inflammation (adjOR 0.7, 95% CI 0.3-1.8) and regression (adjOR 0.6, 95% CI 0.2-1.8) but more frequent histological ulceration (adjOR 1.9, 95% CI 0.6-5.8). In comparison with the population-based material, CDKN2A-associated cases were significantly younger at diagnosis (crude OR 3.5, 95% CI 1.6-7.5, divided at 50 years) and had less regressive reaction in their tumours (crude OR 0.355 95% CI 0.2-0.8). No significant differences were seen for tumour thickness between the different groups. On multivariate analysis, the overall survival was significantly worse for thicker tumours and older age (P=0.04 for both). To our knowledge this is the first description of the histopathological features of CMMs from families with mutations in the CDKN2A gene.

Keywords

  • Cancer and Oncology
  • mutation
  • melanoma
  • histopathology
  • CDKN2A
  • hereditary
  • population-based

Other

Published
  • ISSN: 0960-8931
Åke Borg
Åke Borg
E-mail: ake.borg [at] med.lu.se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2

90

Project manager

Familial Breast Cancer

90

Professor

Oncology and Pathology, MV

MV 404 C21C2

90